July 13, 2021
1 min watch
Save
VIDEO: ‘Reassuring’ long-term survival data from PACIFIC trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Sonam Puri, MD, spoke with Healio about updated findings from the PACIFIC trial presented at this year’s virtual annual ASCO meeting.
Puri, assistant professor in the division of oncology in the department of medicine at the University of Utah, highlighted that while previous findings from the PACIFIC trial have already changed practice, this update provided important information on long-term survival.
“The data was pretty reassuring,” she said. “The 5-year survival rate was 43% in the durvalumab arm vs. 33% in the placebo arm.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Spigel DR, et al. Abstract 8511. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).
Disclosures:
Disclosure: Puri reports serving in an advisory and consulting role for AstraZeneca and G1 Therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.